Targeting thyroid cancer microenvironment: Basic research and clinical applications

Frontiers in Endocrinology

Volumn 4, Issue NOV, 2013, Pages

  Nucera, Carmelo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; BRAFV600E; Extracellular matrix; Microenvironment; Mouse models; Targeted therapy; Thyroid cancer; Translational

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BIOLOGICAL MARKER; INTEGRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR PAX8;

CANCER MORTALITY; CANCER PROGNOSIS; EDITORIAL; ENZYME INHIBITION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSLATIONAL RESEARCH; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84890254497     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00167     Document Type: Editorial

References (14)

1. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R. Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 9(3):178-84. doi: 10.1038/nrendo.2012.257
2. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 381(9871):1058-69. doi:10.1016/S0140-6736(13)60109-9
3. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 309(14):1493-501. doi:10.1001/jama.2013.3190
4. Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (2012) 3:33. doi:10.3389/fendo.2012.00033
5. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2012) 118(8):2069-77. doi:10.1002/cncr.26425
6. Rossi M, Buratto M, Bruni S, Filieri C, Tagliati F, Trasforini G, et al. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol Metab (2012) 97(7):2354-61. doi:10.1210/jc.2011-3494
7. Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 200(1):136-43. doi:10.1016/j.amjsurg.2009.08.029
8. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 121(12):4700-11. doi:10.1172/JCI46382
9. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA (2010) 107(23):10649-54. doi:10.1073/pnas.1004934107
10. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 16(3):296-309. doi:10.1634/theoncologist.2010-0317
11. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 3(5):520-33. doi:10.1158/2159-8290.CD-12-0531
12. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab (2010) 95(5):2325-33. doi:10.1210/jc.2009-2564
13. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 97(6):E934-43. doi:10.1210/jc.2011-3428
14. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 15(4):1069-74. doi:10.1677/ERC-08-0036